- Previous Close
9,800.00 - Open
10,310.00 - Bid 10,950.00 x --
- Ask 10,960.00 x --
- Day's Range
10,300.00 - 11,070.00 - 52 Week Range
7,800.00 - 19,500.00 - Volume
191,115 - Avg. Volume
198,245 - Market Cap (intraday)
232.465B - Beta (5Y Monthly) 0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 29, 2021
- 1y Target Est
--
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inflammatory agents. The company also provides OTC products and sanitary aids. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.
www.samil-pharm.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 000520.KS
View MorePerformance Overview: 000520.KS
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000520.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000520.KS
View MoreValuation Measures
Market Cap
208.05B
Enterprise Value
352.99B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.80
Price/Book (mrq)
1.18
Enterprise Value/Revenue
1.61
Enterprise Value/EBITDA
40.54
Financial Highlights
Profitability and Income Statement
Profit Margin
-2.56%
Return on Assets (ttm)
0.01%
Return on Equity (ttm)
-3.70%
Revenue (ttm)
219.7B
Net Income Avi to Common (ttm)
-5.63B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
5.14B
Total Debt/Equity (mrq)
85.21%
Levered Free Cash Flow (ttm)
-8.44B